A Prospective, Open-ended, Multi-center Study of Schizophrenia Patients Switching to Zolodine
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Through self-controlled studies on metabolic syndrome related indicators, efficacy and other
adverse reactions in patients with schizophrenia who developed metabolic syndrome after
treatment with other antipsychotics, switched to Zoladine capsules (ziprasidone hydrochloride
capsules). To evaluate the clinical application value of switching to Zolodine for
schizophrenia patients with metabolic syndrome, and to explore the drug selection strategy
for long-term treatment of schizophrenia patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University